AMSTERDAM, March 29, 2016 /PRNewswire/ -- Royal Philips
(NYSE: PHG, AEX: PHIA) today announced Massachusetts General
Hospital (MGH) will serve as a key testing site for a
multi-centered instrument precision study involving Philips'
digital pathology whole slide imaging (WSI) IntelliSite Solution.
The study is designed to show the reproducibility of the
IntelliSite pathology solution in disease detection as part of the
industry's efforts to obtain regulatory clearance of WSI for
primary diagnostic use. If approved for diagnosis, in contrast to
the industry's current analog process, soon pathologists could
benefit from a digital system for their routine work.
The pathologist plays a critical role in the detection and
diagnosis of a wide variety of diseases, including cancer. Most
tissue-based diagnoses are rendered through analysis performed on a
microscope using sections on glass slides. Once interpreted by a
pathologist, they inform the final treatment pathway that has a
significant impact on the patient and their families. In the
process, providers often have to ship the glass slide samples for
expert consults, running the risk for lost or damaged specimens and
communication delays.
"With rising health care costs, we have a public responsibility
to work effectively," said Jochen K.
Lennerz, M.D., Ph.D., principal investigator of the study.
"Through the genomic revolution we have started to learn how to
manage big data. Now there is a pressing need to gain access to and
increase flexibility in how pathologists manage the massive amounts
of imaging data we procure every day."
As workloads increase and pressures mount to improve the
diagnostic process, the need to reinvent traditional pathology
workflows to increase efficiencies and better manage massive
amounts of data has put a spotlight on digital pathology solutions.
These technologies have been developed to digitize and streamline
pathology workflows and enhance multi-site collaboration with the
ultimate goal to support pathways to improved diagnosis.
"Through this study we hope to provide evidence for regulatory
purposes that this technology is valid and reliable for primary
diagnostic use," added Veronica E.
Klepeis, M.D., Ph.D., the key enrollment pathologist in the
study.
As the personalized medicine and cancer moonshot movements are
gaining visibility amongst the public, digital pathology's role in
disease diagnostics should not be overlooked. Recent discussions
with the Food and Drug Administration (FDA) have the potential to
streamline the regulatory clearance pathway for digital pathology
WSI moving forward.
"Digital pathology addresses many of the inherent delays present
in traditional pathology workflows and supports workplace
efficiencies that can be scaled within organizations to streamline
processes and cut costs," said Russell
Granzow, General Manager of Philips Digital Pathology
Solutions. "Philips is excited about the clinical study MGH is
conducting to investigate the reproducibility of digital pathology
system in the clinical diagnostic setting."
To learn more about Philips' innovation in digital pathology,
visit Philips' Digital Pathology Solutions website and follow
@Philips.
For further information, please contact:
Steve Klink
Philips Group Communications
Tel.: +31 6 1088 8824
E-mail: steve.klink@philips.com
Hans Driessen
Philips Digital Pathology Solutions
Tel.: +31 6 10610417
E-mail: hans.driessen@philips.com
About Royal
Philips
Royal Philips
(NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people's health and enabling better outcomes
across the health continuum from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to deliver
integrated solutions. The company is a leader in diagnostic
imaging, image-guided therapy, patient monitoring and health
informatics, as well as in consumer health and home care. Philips'
wholly owned subsidiary Philips Lighting is the global leader in
lighting products, systems and services. Headquartered in
the Netherlands, Philips posted
2015 sales of EUR 24.2 billion and
employs approximately 104,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
Logo -
http://photos.prnewswire.com/prnh/20140122/NE50581LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/massachusetts-general-hospital-embarks-on-clinical-analytical-study-using-philips-intellisite-solution-to-advance-digital-pathology-adoption-in-the-united-states-300242340.html
SOURCE Royal Philips